Benefits of pre‐biopsy multi‐parametric magnetic resonance imaging scanning in the initial assessment of prostate cancer

Traditionally, men referred for investigation of raised prostate specific antigen (PSA) could expect to be investigated via blind TRUS biopsy. In recent years, the availability of pre‐biopsy imaging with multi‐parametric magnetic resonance imaging (mp‐MRI) has allowed urology centres to improve their triage and care of this patient cohort. The ability to identify discrete lesions for more accurately targeted TRUS, stream patients with anterior lesions for trans‐perineal biopsy, and of course to prevent those with no evidence of clinically significant prostate cancer from being subjected to unnecessary procedures has proved pre‐biopsy mp‐MRI a valuable tool in the assessment and diagnosis of prostate cancer. Our service recently audited the impact of the introduction of mp‐MRI on our prostate cancer assessment pathway. An analysis of the outcomes of 1558 referrals over a 2‐year period, and found that pre‐biopsy imaging has resulted in a marked reduction in unnecessary procedures and more accurate targeting of lesions, leading to improved outcomes for patients.     

Multiparametric Ultrasound for Targeting Prostate Cancer: Combining ARFI,SWEI, QUS and B-Mode

Diagnosing prostate cancer through standard transrectal ultrasound (TRUS)-guided biopsy is challenging because of the sensitivity and specificity limitations of B-mode imaging. We used a linear support vector machine (SVM) to combine standard TRUS imaging data with acoustic radiation force impulse (ARFI) imaging data, shear wave elasticity imaging (SWEI) data and quantitative ultrasound (QUS) midband fit data to enhance lesion contrast into a synthesized multiparametric ultrasound volume. This SVM was trained and validated using a subset of 20 patients and tested on a second subset of 10 patients. Multiparametric US led to a statistically significant improvements in contrast, contrast-to-noise ratio (CNR) and generalized CNR (gCNR) when compared with standard TRUS B-mode and SWEI; in contrast and CNR when compared with MF; and in CNR when compared with ARFI. ARFI, MF and SWEI also outperformed TRUS B-mode in contrast, with MF outperforming B-mode in CNR and gCNR as well. ARFI, although only yielding statistically significant differences in contrast compared with TRUS B-mode, captured critical qualitative features for lesion identification. Multiparametric US enhanced lesion visibility metrics and is a promising technique for targeted TRUS-guided prostate biopsy in the future.     

经直肠多模态超声影像评分系统诊断前列腺癌的临床研究

目的建立前列腺癌多模态超声影像评分系统,并评价该评分系统对前列腺癌的诊断价值。 方法选取2016年5月至2017年12月在解放军总医院行超声引导下穿刺活检和（或）手术切除的86例可疑前列腺癌患者,术前对前列腺行经直肠常规超声、剪切波弹性成像、超声造影检查,分析三种模态超声影像特征,并与手术或穿刺病理进行对照。总结前列腺癌经直肠多模态超声影像特征,建立评分系统,并评价该系统对前列腺癌的诊断价值。 结果前列腺癌常规超声表现为低回声、边界不清、形态不规则、内外腺分界不清、包膜侵犯、血流信号丰富且为中心血流;剪切波弹性成像表现为非对称分布,前列腺癌病灶平均弹性模量高于良性病灶［（94.7±44.2）kPa vs（60.8±26.0）kPa］,差异有统计学意义（t=-3.578,P=0.001）;超声造影表现为快速高增强,分布不均匀（低增强区伴点状血管结构,点状、片状或结节状高增强）,内外腺分界不清,包膜或直肠壁侵犯。常规超声、超声造影、弹性成像有1项阳性即诊断为前列腺癌,其敏感度、阴性预测值和准确性分别为98.0%、96.7%和89.5%;三者均为阳性诊断为前列腺癌,其特异度和阳性预测值分别为97.3%和97.1%。 结论经直肠多模态超声影像评分系统可提高超声对前列腺癌的诊断价值。     

Contrast‐Enhanced Sonographically Guided Thermal Ablation for Treatment of Solid‐Organ Hemorrhage

The purpose of this series was to preliminarily evaluate the use of contrast‐enhanced sonographically guided percutaneous thermal ablation in the evaluation and treatment of solid‐organ bleeding by retrospectively analyzing 6 cases observed in clinical practice. Six patients who underwent contrast‐enhanced sonographically guided thermal ablation for treatment of solid‐organ bleeding (5 in liver and 1 in spleen) from December 2005 to August 2012 were included in this series. Clinical information, contrast‐enhanced sonograms before and after ablation, and the ablation method were retrospectively collected and analyzed. In 5 of the 6 patients, the location of the bleeding lesion was clearly seen. Hemostasis was successfully achieved in 4 of these 5 patients: 1 by radiofrequency ablation and 3 by microwave ablation. Ablation failed to achieve hemostasis in 1 patient who had postbiopsy splenic arterial bleeding because the bleeding vessel was a thick branch of the splenic artery. In the sixth remaining patient, who had bleeding after liver biopsy, hemostasis failed because contrast‐enhanced sonography did not precisely locate the bleeding lesion; hence, the ablation zone did not cover the whole lesion. Contrast‐enhanced sonographically guided ablation can be an alternative choice for treating solid‐organ bleeding because of its effectiveness and minimal invasiveness. However, it should be carefully investigated for those in whom the bleeding lesion cannot be located by contrast‐enhanced sonography and in those who have bleeding in a large vessel.     

经直肠实时组织弹性成像联合峰值应变指数靶向穿刺活检诊断外周带前列腺癌的价值

目的 探讨经直肠实时组织弹性成像（TRTE）联合峰值应变指数（PSI）靶向穿刺活检诊断外周带前列腺癌的应用价值。方法 选取于我院就诊的127例疑似外周带前列腺癌患者,均行经直肠超声（TRUS）和TRTE检查,计算PSI;然后行TRUS系统穿刺活检、TRTE联合PSI靶向穿刺活检,根据手术病理结果分为前列腺癌组92例和良性病变组35例,比较两组PSI和各临床资料的差异;比较TRUS系统穿刺活检与TRTE联合PSI靶向穿刺活检对外周带前列腺癌的检出率及穿刺点阳性率;绘制受试者工作特征（ROC）曲线分析TRTE联合PSI靶向穿刺活检对外周带前列腺癌的诊断效能。结果 前列腺癌组PSI、血清前列腺特异性抗原（PSA）均高于良性病变组,差异均有统计学意义（均P<0.001）。92例外周带前列腺癌患者中,TRTE联合PSI靶向穿刺活检诊断85例,TRUS系统穿刺活检诊断78例,二者对外周带前列腺癌的检出率比较（66.9%vs. 61.4%）,差异无统计学意义。127例患者共穿刺1524针,其中TRUS系统穿刺1270针,TRTE联合PSI靶向穿刺254针,二者穿刺点阳性率比较（17.9%vs....     

前列腺癌经直肠超声声像图与病理对照

目的 本文观察前列腺癌部位声像图特点并与病理对照,以便帮助穿刺点的正确选择,提高前列腺穿刺活检阳性率。方法 总结71例经病理证实为前列腺癌的125个部位的经直肠超声声像图,观察有无异常回声肿块和异常血流区域,以及肿块的超声回声类型和边界情况。结果 125个前列腺癌部位其经直肠超声（TRUS）检查发现异常的有100个,占80％;TRUS检查未发现可疑之处的为25例,占20％。结论 TRUS可作为前列腺穿刺活检穿刺点选择的重要方法。     

超声造影对高强度聚焦超声联合肝动脉栓塞化疗治疗肝癌的疗效评价

目的探讨超声造影(CEUS)评价高强度聚焦超声(HIFU)联合肝动脉栓塞化疗(TAE)治疗肝恶性肿瘤疗效的应用价值。方法 24例肝癌患者,其中原发性肝癌15例,转移癌9例,治疗病灶总计31个,TAE治疗后1周内行HIFU治疗,于治疗前和治疗后7～14 d行CEUS检查,并与同期彩色多普勒超声(CDFI)、增强MRI检查结果比较。结果 CEUS观察31个病灶治疗覆盖区,19个(61.3%)在各期均为无增强,提示肿瘤完全灭活,12个(38.7%)病灶边缘或中央局部动脉期高增强,门脉期或延迟期减退为低增强,提示为肿瘤残存。以最终诊断为金标准,CEUS诊断准确性90.3%,增强MRI为93.5%,彩色多普勒超声为48.4%。CEUS与增强MRI在评价肿瘤灭活方面的敏感性、特异性、准确性差异均无统计学意义(P>0.05),CEUS对肿瘤灭活诊断的准确性高于CDFI(P<0.05)。结论 CEUS可较准确地判断HIFU联合TAE治疗后肿瘤灭活程度,可为肝癌治疗近期疗效评价提供依据,有较高临床应用价值。     

经直肠超声诊断前列腺癌的临床价值

目的探讨经直肠超声检查前列腺癌的临床价值。方法应用经直肠超声对临床拟诊53例前列腺癌患进行检查，观察前列腺内腺及外腺回声，发现形态不规则低回声区，仔细分辨与周围组织的关系，并行彩色及能量多普勒血流显像。结果经穿刺活检及手术病理证实46例为前列腺癌，7例为前列腺增生，诊断符合率为86．8％。结论经直肠超声显示前列腺癌声像图的敏感性及特征性较腹部超声明显增高，结合直肠指检(DRE)及前列腺特异性抗原(PSA)测定可提高前列腺癌的检出率。     

超声造影诊断前列腺良恶性病变的价值

目的 探讨经直肠超声造影在诊断前列腺良恶性病变中的价值.方法 对60例血清前列腺特异性抗原增高并疑有前列腺疾病患者行经直肠超声榆查,采用SonoVue造影剂结合CPS造影成像技术行超声造影,并观察造影增强方式及增强强度,造影结束同时对患者行经直肠超声引导穿刺活检.对其中38例良、恶性结节患者用ACQ软件绘制时间-强度曲线(TIC),分析造影参数,比较良、恶性间的差异.结果 60例前列腺疾病患者均得到病理证实.良性病变37例,其中结节性病变15例共20个结节,前列腺增生22例.恶性病变23例,结节病灶18例18个,弥漫性病变5例.内腺良性结节超声造影增强方式以均匀增强为主,结节边界清晰;恶性结节以早于正常外腺组织增强为主.恶性结节达峰时间及加速时间均短于良性结节(P<0.05),峰值强度低于良性结节(P<0.05),到达时间良、恶性间差异无统计学意义(P>0.05).超声造影对前列腺病变的良恶性鉴别诊断符合率要高于常规经直肠超声(P<0.05).超声造影诊断的敏感度、特异度和正确率均高于常规经直肠超声,而误诊率、漏诊率均小于常规经直肠超声.结论 经直肠超声造影对前列腺癌的早期发现及对良恶性病变的鉴别诊断均具有一定的临床应用价值.     

子宫肌瘤超声消融后子宫浆肌层损伤早期MRI影像学特征及临床意义

目的探究子宫肌瘤超声消融后子宫浆肌层损伤早期MRI影像学特征及其临床意义。方法回顾性分析2019年9月~2020年9月在本院接受高强度聚焦超声（HIFU）消融术治疗的150例子宫肌瘤患者的临床资料,所有患者均于手术前后接受MR检查,影像学资料完整。比较手术前后患者的MRI信号改变情况,根据MRI图像特征确定术后患者子宫浆肌层损伤情况,将患者分为损伤组（n=43）和无损伤组（n=107）,观察损伤组患者的MRI形态特征,比较两组患者的超声消融情况及术后不良反应发生情况。结果术前,子宫肌瘤在T1WI上表现为低、等或高信号,在T2WI上表现为低或高低混杂信号、等信号或高信号,增强扫描均显示强化;术后肌瘤T1WI信号增高,T2WI信号变化无明显规律,增强扫描均显示无强化。超声消融后,子宫浆肌层损伤率为28.67%（43/150）,子宫浆肌层损伤的MRI表现为：T2WI序列显示肌瘤周边肌层信号连续,边界清晰;动态增强扫描显示子宫浆肌层呈环状强化,局部灌注缺损,前壁肌瘤的宫浆肌层损伤率最高为31.40%。损伤组的辐照时间、消融总剂量和肌瘤体积消融率均高于无损伤组（P < 0.05）,术后两组患者均出现一定不良反应,且损伤组患者阴道排液发生率高于无损伤组（P < 0.05）。结论子宫肌瘤患者接受HIFU消融术治疗后,早期会出现子宫浆肌层损伤,治疗期间的辐照时间长、消融总剂量及肌瘤体积消融率高会增加患者子宫浆肌层损伤的风险,使患者术后出现不良反应,通过MRI检查可有效评估患者的子宫浆肌层损伤情况。     

经直肠超声及其穿刺活检对前列腺增生与前列腺癌的鉴别诊断价值

目的 评价经直肠超声检查及其穿刺活检对鉴别前列腺增生症与前列腺癌的价值。方法 将40例前列腺疾病患者术后病理分组，与术前经直肠超声检查声像图以及13例穿刺活检结果对照分析。结果 术后前列腺增生组27例，前列腺增生伴炎症组4例，前列腺癌组9例，术前经直肠超声检查诊断前列腺增生27例，疑诊前列腺癌13例并行穿刺活检，其中6例术前穿刺确诊为前列腺癌，3例前列腺癌未穿刺，但术后病理证实，经直肠前列腺癌超声诊断敏感性66．7％，特异性77．4％，准确性75％；而本组穿刺活检对前列腺癌选择性检出率为46．2％，其准确性、敏感性、特异性均为100％。结论 经直肠二维及彩色多普勒超声检查对于鉴别良性前列腺增生症与前列腺癌有着重要价值，可以选择性提高穿刺活检中前列腺癌的检出率，而结合经直肠超声检查的前列腺穿刺活检术则是发现并确诊前列腺癌的有效方法。     

高强度聚焦超声治疗放疗后残留肝癌的初步临床观察

目的 探讨高强度聚焦超声(HIFU)治疗放疗后残留肝癌的安全性和有效性.方法 HIFU治疗20例三维适形、立体定向放疗后25个肝癌残留病灶,比较HIFU治疗前、治疗后1周肝功能和血细胞变化,及治疗前、治疗后2周MRI、AFP变化,并行生存分析.结果 平均随访(12.6±8.0)个月,中位生存时间、1年生存率分别为22个月、87.5%.所有患者无皮肤烧伤.白蛋白、谷丙转氨酶、谷草转氨酶、总胆红素、直接胆红素、红细胞、白细胞、血小板HIFU治疗前与治疗后1周比较,差异无统计学意义(P=0.156、0.356、0.203、0.659、0.531、0.519、0.310、0.346).AFP(9例阳性)HIFU治疗前与治疗后2周比较,差异有统计学意义(P=0.030).MRI示16个病灶完整消融,6个消融体积≥80%.结论 HIFU可能是一种安全、有效治疗适形、立体定向放疗后残留肝癌的新方法.

Abstract：

Objective To investigate the safety and effect of high intensity focused ultrasound ablation(HIFU) on residual liver cancer in patients after radiotherapy. Methods Twenty liver cancer patients with twenty five residual tumors after three-dimensional conformal radiotherapy or stereotactic radiotherapy received HIFU ablation. Liver function and periphery blood cell counts were performed before HIFU and at 1 week after HIFU in all patients. Enhanced MRI and α-fetoprotein (AFP) level were performed before HIFU and at 2 weeks after HIFU to evaluate the effect of HIFU ablation. The survival of all patients was assessed by the Kaplan-Meier method. Results The mean follow-up time was (12.6 ± 8.0)months. The median survival time and 1-year survival rate were 22 months and 87.5% respectively. No skin burns were observed in all patients. As compared with before HIFU,there were no significant differences in the levels of albumin,alanine transarninase, aspartate transarninase, total bilirubin, direct bilirubin, blood red cell counts,blood white cell counts and blood platelet counts at 1 week after HIFU (paired t test, P =0. 156,0. 356,0. 203,0.659,0. 531,0. 519,0. 310,0. 346, respectively). Significant difference in AFP level of 9 patients with AFP＞20 μg/L was observed before HIFU and 2 weeks after HIFU (paired t test, P =0.030). Among 25 residual liver tumors,sixteen with complete ablation and six with ablation volume of ≥80% were observed by enhanced MRI at 2 weeks after HIFU. Conclusions HIFU may be a safe and effective new method to ablate residual liver cancer after three-dimensional conformal radiotherapy or stereotactic radiotherapy.     

3D prostate model formation from non-parallel 2D ultrasound biopsy images

Biopsy of the prostate using 2D transrectal ultrasound (TRUS) guidance is the current gold standard for diagnosis of prostate cancer; however, the current procedure is limited by using 2D biopsy tools to target 3D biopsy locations. We propose a technique for patient-specific 3D prostate model reconstruction from a sparse collection of non-parallel 2D TRUS biopsy images. Our method conforms to the restrictions of current TRUS biopsy equipment and could be efficiently incorporated into current clinical biopsy procedures for needle guidance without the need for expensive hardware additions. In this paper, the model reconstruction technique is evaluated using simulated biopsy images from 3D TRUS prostate images of 10 biopsy patients. All reconstructed models are compared to their corresponding 3D manually segmented prostate models for evaluation of prostate volume accuracy and surface errors (both regional and global). The number of 2D TRUS biopsy images used for prostate modeling was varied to determine the optimal number of images necessary for accurate prostate surface estimation.     

Image Registration Accuracy of a 3‐Dimensional Transrectal Ultrasound–Guided Prostate Biopsy System

Objective. For a follow‐up prostate biopsy procedure, it is useful to know the previous biopsy locations in anatomic relation to the current transrectal ultrasound (TRUS) scan. The goal of this study was to validate the performance of a 3‐dimensional TRUS‐guided prostate biopsy system that can accurately relocate previous biopsy sites. Methods. To correlate biopsy locations from a sequence of visits by a patient, the prostate surface data obtained from a previous visit needs to be registered to the follow‐up visits. Two interpolation methods, thin‐plate spline (TPS) and elastic warping (EW), were tested for registration of the TRUS prostate image to follow‐up scans. We validated our biopsy system using a custom‐built phantom. Beads were embedded inside the phantom and were located in each TRUS scan. We recorded the locations of the beads before and after pressures were applied to the phantom and then compared them with computer‐estimated positions to measure performance. Results. In our experiments, before system processing, the mean target registration error (TRE) ± SD was 6.4 ± 4.5 mm (range, 3–13 mm). After registration and TPS interpolation, the TRE was 5.0 ± 1.03 mm (range, 2–8 mm). After registration and EW interpolation, the TRE was 2.7 ± 0.99 mm (range, 1–4 mm). Elastic warping was significantly better than the TPS in most cases (P < .0011). For clinical applications, EW can be implemented on a graphics processing unit with an execution time of less than 2.5 seconds. Conclusions. Elastic warping interpolation yields more accurate results than the TPS for registration of TRUS prostate images. Experimental results indicate potential for clinical application of this method.     

Targeted prostate biopsy and MR-guided therapy for prostate cancer

Prostate cancer is the most commonly diagnosed noncutaneous cancer and second-leading cause of death in men. Many patients with clinically organ-confined prostate cancer undergo definitive treatment of the whole gland including radical prostatectomy, radiation therapy, and cryosurgery. Active surveillance is a growing alternative option for patients with documented low-volume, low-grade prostate cancer. With recent advances in software and hardware of MRI, multiparametric MRI of the prostate has been shown to improve the accuracy in detecting and characterizing clinically significant prostate cancer. Targeted biopsy is increasingly utilized to improve the yield of MR-detected, clinically significant prostate cancer and to decrease in detection of indolent prostate cancer. MR-guided targeted biopsy techniques include cognitive MR fusion TRUS biopsy, in-bore transrectal targeted biopsy using robotic transrectal device, and in-bore direct MR-guided transperineal biopsy with a software-based transperineal grid template. In addition, advances in MR compatible thermal ablation technology allow accurate focal or regional delivery of optimal thermal energy to the biopsy-proved, MRI-detected tumor, utilizing cryoablation, laser ablation, high-intensity focused ultrasound ablation under MR guidance and real-time or near simultaneous monitoring of the ablation zone. Herein we present a contemporary review of MR-guided targeted biopsy techniques of MR-detected lesions as well as MR-guided focal or regional thermal ablative therapies for localized naïve and recurrent cancerous foci of the prostate.     

高强度聚焦超声治疗特殊前列腺癌的现状及进展

前列腺癌现已成为危害男性健康的常见泌尿系统肿瘤之一,我国前列腺癌的发病率不断上升。前列腺癌的治疗已成为目前的热门话题。高强度聚焦超声（high intensity focused ultrasound, HIFU）是一种将超声聚焦形成高能量的焦域从而杀灭靶组织新技术。HIFU在一些报道中已单独用来治疗早期局限性前列腺癌,疗效确切。同时,HIFU对于几种特殊的前列腺癌,如激素非依赖性前列腺癌、放疗后复发前列腺癌以及HIFU治疗后复发的前列腺癌也起到了一定的作用。     

多参数MRI前列腺影像报告和数据系统评分与经直肠超声引导下穿刺病理的相关性分析

目的旨在探讨多参数MRI(multi-parametric MRI,Mp-MRI)前列腺影像报告和数据系统(prostate imaging reporting and data system version 2,PI-RADS V2)评分与经直肠超声引导下穿刺病理的相关性。材料与方法回顾性分析经病理证实的128例前列腺病变患者的MRI资料,其中前列腺癌75例,良性前列腺增生48例、前列腺炎5例,所有患者均行3.0 T MRI扫描,获取完整的T2WI、DWI及DCE图像;由2名前列腺诊断医师在不知患者临床资料及病理的情况下采用PIRADS V2评分标准进行评分,评分结果分别记录;所有患者均行经直肠超声引导下病理穿刺,并由泌尿专业病理诊断医师进行诊断,对前列腺癌则进行Gleason评分。采用Spearman相关分析PI-RADS V2评分与穿刺病理的相关系数,并采用ROC曲线分析PI-RADS V2评分诊断前列腺癌的敏感性、特异性和准确性。结果 PI-RADS V2评分与穿刺病理呈正相关,r=0.887。PI-RADS V2评分诊断前列腺癌的ROC曲线下面积0.975,其敏感性为93.33%,特异性为96.23%,准确性为94.51%,阳性预测值97.22%,阴性预测值91.07%。Gleason评分≥8分的前列腺癌的PI-RADS V2评分为5分。结论 PI-RADS V2评分与经直肠超声引导下穿刺病理的相关性高,PI-RADS V2评分对前列腺疾病的诊断准确性高。     

高强度聚焦超声治疗子宫平滑肌瘤的病理变化及其超声随访研究

目的通过病理穿刺及超声随访探讨高强度聚焦超声（HIFU）治疗子宫肌瘤的有效性。方法62例经HIFU治疗的子宫肌瘤患者，术前、术后1周分别进行超声引导下穿刺活检，标本行光镜和电镜观察。并分别在术后1、3、6和12个月进行超声检查，计算瘤体均径并与治疗前均径比较。结果光镜和电镜显示HIFU治疗后子宫肌瘤组织明显的细胞坏死、核固缩浓染、核碎裂溶解以及细胞器的破坏；同时可见血管的破坏以及空泡的形成。超声随访显示治疗后1个月肌瘤出现缩小，治疗后3个月瘤体明显缩小，与治疗前相比有显著差异（P〈0．05）。结论病理检查和超声随访证实HIFU治疗子宫平滑肌瘤明确有效。     

Contrast‐enhanced ultrasound findings in a case of renal extramedullary hematopoiesis

We present the case of an 80‐year‐old man with two renal solid masses found at sonography, which were imaged by contrast‐enhanced ultrasound, CT, and MRI and confirmed histologically. Contrast‐enhanced ultrasound findings suggested a benign mass and a CT‐guided biopsy yielded a diagnosis of extramedullary hematopoiesis. © 2012 Wiley Periodicals, Inc. J Clin Ultrasound, 2013     

经直肠超声引导下徒手经会阴前列腺穿刺在前列腺病变中的应用

目的探讨在经直肠前列腺超声引导下徒手对前列腺穿刺活检诊断前列腺良恶性病变中的临床价值。方法选取2019年2月~2020年1月在中国科学技术大学附属第一医院南区就诊的临床疑似前列腺癌并行经会阴前列腺穿刺活检患者62例,依最终病理结果分为2组：前列腺癌组,共25例,男性,年龄55~82岁;前列腺良性病变组,共37例,男性,年龄54~83岁。经直肠超声分别观察记录两组前列腺大小、内部回声及有无异常回声、回声大小范围,并按部位系统穿刺及目标靶向性穿刺,对比分析两组间临床资料以及前列腺病变特征。结果前列腺癌组病理类型均为前列腺腺癌（包括腺泡癌）,良性病变组患者病理提示正常前列腺组织、腺体及间质增生、肌肉以及纤维组织。前列腺癌组穿刺取得组织中共145条病理结果为前列腺癌,108条（75%）位于前列腺周缘区穿刺点,癌组织占比标本组织长度大于50%的有81条（56%）。经直肠超声共发现52个异常回声,均穿刺取得病理,对比分析发现不同大小的低回声其病理成分不同,差异有统计学意义（P < 0.05）。结论经直肠超声引导下经会阴前列腺穿刺对前列腺周缘区有优势性并可对可疑病变区域直观准确的目标性穿刺,对于前列腺良恶性病变的诊断具有重要意义。